Upcoming Events More events are coming soon. Past Events Aug 12, 2026 8:30 AM EDT NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Mar 4, 2026 9:00 AM EST NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity Nov 12, 2025 9:00 AM EST Presenting Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
Upcoming Events More events are coming soon. Past Events Aug 12, 2026 8:30 AM EDT NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Mar 4, 2026 9:00 AM EST NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity Nov 12, 2025 9:00 AM EST Presenting Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
Aug 12, 2026 8:30 AM EDT NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Mar 4, 2026 9:00 AM EST NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
Nov 12, 2025 9:00 AM EST Presenting Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program